Carvallo et al. Ivermectin for COVID-19 EARLY
Is early treatment with ivermectin+combined treatments beneficial for COVID-19?
Prospective study of 46 patients in Argentina
Lower mortality with ivermectin+combined treatments
(not stat. sig., p=0.078)
Carvallo et al., J. Clinical Trials, 11:459
Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against COVID-19 the I.D.E.A. Protocol
Carvallo et al., Journal of Clinical Trials, 11:459 (date from earlier preprint)
Carvallo et al., Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against COVID-19.., Journal of Clinical Trials, 11:459 (date from earlier preprint)
Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin, showing no hospitalization for mild cases, and lower mortality for moderate/severe patients.
This study is excluded in the after exclusion results of meta
minimal details of groups provided.
risk of death, , treatment 1 of 32 (3.1%), control 3 of 14 (21.4%), NNT 5.5, moderate/severe patients, the only treatment death was a patient already in the ICU before treatment, primary outcome.
85.4% lower, RR 0.15, p = 0.08
Effect extraction follows
pre-specified rules prioritizing more serious outcomes. Submit updates
Carvallo et al., 15 Sep 2020, prospective, Argentina, peer-reviewed, mean age 55.7, 3 authors, dosage 36mg days 1, 8, dose varied depending on patient condition - mild 24mg, moderate 36mg, severe 48mg, this trial uses multiple treatments in the treatment arm (combined with dexamethasone, enoxaparin, and aspirin) - results of individual treatments may vary.
Journal of Clinical Trials
Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone,
Enoxaparin and Aspirina against COVID-19 the I.D.E.A. Protocol
Carvallo Hector1*, Hirsch Roberto2
of Internal Medicine, Universidad Abierta Internamericana, San Juan, Argentina; 2Department of Infectology,
Universidad de Buenos Aires, Caba, Argentina
From the first outbreak in Wuhan (China) in December 2019, until today (05/28/2020), the number of deaths
worldwide due to the coronavirus pandemic exceeded 2.5 millions.
Only in Argentina, 50,000 deaths have been confirmed so far. There haven’t been so far any clear diagnostic pattern
for this exceptional entity except unilateral skin involvement, early onset of symptoms, positive ANA and negative
tests for Borrelia burgdorferi. Hence, we report a new case of a young Moroccan man.
No treatment tested worldwide has shown unquestionable efficacy in the fight against COVID-19, according to
W.H.O, NIH and NICE reports and accumulated data.
Our proposal consists of the combination of drugs, based on the pathophysiology of the virus. We have designed a
treatment called I.D.E.A., based on four affordable drugs already available on the pharmacopoeia in Argentina, on
the following rationale:
-Ivermectin (IVM) solution to lower the viral load in all stages of COVID-19.
-Dexamethasone 4 mg injection, as anti-inflammatory drug to treat hyperinflammatory reaction to COVID-infection.
-Enoxaparin injection as anticoagulant to treat hypercoagulation in severe cases.
-Aspirin 250 mg tablets to prevent hypercoagulation in mild and moderate cases.
Except for Ivermection oral solution, which was used in a higher dose than approved for parasitosis, all other drugs
were used in the already approved dose and indication. Regarding Ivermectin safety, several oral studies have shown
it to be safe even when used at daily doses much higher than those approved already. A clinical study has
been conducted on COVID-19 patients at Eurnekian Hospital in the Province of Buenos Aires, Argentina. The
study protocol and its final outcomes are described in this article. Results were compared with published data
and data from patients admitted to the hospital receiving other treatments.
None of the patient presenting mild symptoms needed to be hospitalized. Only one patient died (0.59% of all
included patients vs. 2.1% overall mortality for the disease in Argentina today, 3.1% of hospitalized patients vs.
26.8% mortality in published data). I.D.E.A. protocol has proved to be a very effective alternative to prevent disease
progression of COVID-19 when applied to mild cases, and to decrease mortality in patients at all stages of the disease
with a favorable risk-benefit ratio.
Keywords: Ivermectin; Aspirin; Dexamethasone; Enoxaparin; COVID-19
Correspondence to: Carvallo Hector, Department of Internal Medicine, Universidad Abierta Internamericana, San Juan, Argentina, E-mail:
Received date: February 16, 2021; Accepted date: March 02, 2021; Published date: March 09, 2021
Citation: Hector C, Roberto H (2021) Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against
COVID-19 the I.D.E.A. Protocol. J Clin Trials. 11:459.
Copyright: © 2021 Hector C, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
provide treatment protocols.